Intratumoral CD3+ T-Lymphocytes Immunoexpression and Its Association with c-Kit, Angiogenesis, and Overall Survival in Malignant Canine Mammary Tumors

Table 1

Relationship of CD3/c-kit, CD3/VEGF, and c-kit/VEGF groups with clinicopathological variables of tumor aggressiveness.

		Variables of tumor aggressiveness
Molecular markers		HGM			Neoplastic intravascular emboli			Lymph node metastasis
		Low (I/II)	High (III)		Absent	Present		Absent	Present
CD3/c-kit	Low CD3/low c-kit	18	4	<0.0001	20	2	<0.0001	18	4	<0.0001
	Low CD3/high c-kit or high CD3/low c-kit	19	16		27	8		24	11
	High CD3/high c-kit	3	20		8	15		7	16
CD3/VEGF	Low CD3/low VEGF	17	3	<0.0001	18	2	<0.0001	16	4	<0.0001
	Low CD3/high VEGF or high CD3/low VEGF	21	14		28	7		26	9
	High CD3/high VEGF	2	23		9	16		7	18
c-kit/VEGF	Low c-kit/low VEGF	10	2	<0.0001	12	0	0.002	11	1	<0.0001
	Low c-kit/high VEGF or high c-kit/low VEGF	20	6		22	4		21	5
	High c-kit/high VEGF	10	32		21	21		17	25

, number of samples; , statistical significance; NS, not significant.